Analyst Research

Report Title Price
Provider: S&P Capital IQ Quantitative Report
$115.00
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Isis Pharmaceuticals Inc's ISIS-TTR Secures Fast Track Designation


Thursday, 13 Dec 2012 08:00am EST 

Isis Pharmaceuticals Inc announced that the United States Food and Drug administration has granted ISIS-TTR fast track designation for the treatment of familial amyloid polyneuropathy (FAP). ISIS-TTR is an antisense drug in development with GlaxoSmithKline (GSK) for the treatment of transthyretin (TTR) amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues. Isis and GSK recently amended the clinical development plan and financial terms relating to ISIS-TTR to support a registration-directed Phase 2/3 clinical study on ISIS-TTR, which is expected to start this month. 

Company Quote

42.28
0.4 +0.96%
19 Sep 2014